NASDAQ:MRTXMirati Therapeutics Stock Price, Forecast & News

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRTX stock has increased by 31.3% and is now trading at $101.62. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mirati Therapeutics.

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Mirati Therapeutics.

Mirati Therapeutics Inc (NASDAQ:MRTX) posted its earnings results on Thursday, May, 7th. The biotechnology company reported ($2.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.66) by $0.36. The biotechnology company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.29 million. Mirati Therapeutics had a negative return on equity of 53.25% and a negative net margin of 10,983.84%. The business's revenue was down 78.5% on a year-over-year basis. View Mirati Therapeutics' earnings history.

17 Wall Street analysts have issued 12 month target prices for Mirati Therapeutics' shares. Their forecasts range from $83.00 to $151.00. On average, they anticipate Mirati Therapeutics' stock price to reach $113.56 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price. View analysts' price targets for Mirati Therapeutics.

News articles about MRTX stock have been trending negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mirati Therapeutics earned a news impact score of -2.1 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutMirati Therapeutics.

Some companies that are related to Mirati Therapeutics include BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Mylan (MYL) and ACADIA Pharmaceuticals (ACAD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), DexCom (DXCM), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Paypal (PYPL), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.84%), Janus Henderson Group PLC (5.38%), Sands Capital Management LLC (5.15%), Wellington Management Group LLP (3.98%), Orbimed Advisors LLC (3.26%) and State Street Corp (2.91%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Isan Chen, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View institutional ownership trends for Mirati Therapeutics.

MRTX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Two Sigma Advisers LP, Pictet Asset Management Ltd., Lord Abbett & CO. LLC, Ghost Tree Capital LLC, Rafferty Asset Management LLC, and Eaton Vance Management. Company insiders that have sold Mirati Therapeutics company stock in the last year include Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Isan Chen, and Michael G Grey. View insider buying and selling activity for Mirati Therapeutics.

MRTX stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Sands Capital Management LLC, Janus Henderson Group PLC, BlackRock Inc., Orbimed Advisors LLC, Geode Capital Management LLC, Nuveen Asset Management LLC, and Castleark Management LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, and Venbio Select Advisor Llc. View insider buying and selling activity for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $101.62.

Mirati Therapeutics has a market capitalization of $4.43 billion and generates $3.34 million in revenue each year. The biotechnology company earns $-213,260,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.

The official website for Mirati Therapeutics is www.mirati.com.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]